

Gerard Espinosa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7820441/publications.pdf>

Version: 2024-02-01

416
papers

13,991
citations

14655

66
h-index

32842

100
g-index

446
all docs

446
docs citations

446
times ranked

10463
citing authors

#	ARTICLE	IF	CITATIONS
1	Presumed tuberculosis-related scleritis. <i>British Journal of Ophthalmology</i> , 2023, 107, 495-499.	3.9	3
2	Clinico-pathological phenotypes of systemic sclerosis-associated myopathy: analysis of a large multicentre cohort. <i>Rheumatology</i> , 2023, 62, S182-S190.	1.9	8
3	Anti-Polymyositis/Scl Antibodies in Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e180-e188.	0.9	6
4	COVID-19 coagulopathy and antiphospholipid syndrome. <i>Revista Colombiana De Reumatología</i> , 2022, 29, S25-S34.	0.1	1
5	Usefulness of high-frequency ultrasonography in the evaluation and monitoring of sclerosing dermatoses: a cohort study. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 351-358.	1.3	9
6	The presence of non-criteria manifestations negatively affects the prognosis of seronegative antiphospholipid syndrome patients: a multicenter study. <i>Arthritis Research and Therapy</i> , 2022, 24, 9.	3.5	4
7	Assessing and counteracting fibrosis is a cornerstone of the treatment of CKD secondary to systemic and renal limited autoimmune disorders. <i>Autoimmunity Reviews</i> , 2022, 21, 103014.	5.8	11
8	Cost-effectiveness analysis of treatments for the first episode of catastrophic antiphospholipid syndrome: A study based on the catastrophic antiphospholipid syndrome registry. <i>Lupus</i> , 2022, 31, 194-201.	1.6	0
9	Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the CAPS Registry. <i>Autoimmunity Reviews</i> , 2022, 21, 103055.	5.8	34
10	Lung involvement in SLE. <i>Handbook of Systemic Autoimmune Diseases</i> , 2022, , 41-53.	0.1	0
11	Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge. <i>Respiratory Research</i> , 2022, 23, 37.	3.6	23
12	Enfermedades autoinmunes y vacunas contra la COVID-19. Toma de decisiones en escenarios de incertidumbre. <i>Medicina Clínica</i> , 2022, , .	0.6	0
13	Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines. <i>European Journal of Internal Medicine</i> , 2022, 99, 19-21.	2.2	4
14	Systemic sclerosis and pregnancy outcomes: a retrospective study from a single center. <i>Arthritis Research and Therapy</i> , 2022, 24, 91.	3.5	3
15	Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4946.	4.1	7
16	Gastrointestinal Involvement in Dermatomyositis. <i>Diagnostics</i> , 2022, 12, 1200.	2.6	6
17	Kidney biopsy in lupus nephritis after achieving clinical renal remission: paving the way for renal outcome assessment. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2081-2088.	2.9	5
18	The clinical significance of low complement levels in patients with catastrophic antiphospholipid syndrome: A descriptive analysis of 73 patients from the Catastrophic antiphospholipid syndrome registry. <i>Lupus</i> , 2022, 31, 1218-1225.	1.6	4

#	ARTICLE	IF	CITATIONS
19	Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre. <i>Lupus</i> , 2022, 31, 1344-1354.	1.6	4
20	Development and implementation of the AIDA International Registry for patients with Behçet's disease. <i>Internal and Emergency Medicine</i> , 2022, 17, 1977-1986.	2.0	11
21	Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 1591-1598.	1.8	1
22	Multidisciplinary care and units for uveitis in the internal medicine departments in Spain: Survey of the Systemic Autoimmune Diseases Group. <i>Revista Clínica Española</i> , 2021, 221, 221-225.	0.5	1
23	Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 125-131.	0.3	6
24	Pregnancy control in patients with systemic lupus erythematosus and antiphospholipid syndrome. Part 1: Infertility, ovarian preservation and preconception assessment. Consensus Document of the Spanish Society of Gynaecology and Obstetrics (SEGO), the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Rheumatology (SER). <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 61-66.	0.3	2
25	COVID-19 and Behçet's disease: clinical case series. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e41-e41.	0.9	17
26	Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy. <i>Lupus</i> , 2021, 30, 134-140.	1.6	5
27	Comment on: EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. <i>Rheumatology</i> , 2021, 60, e181-e183.	1.9	1
28	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	6.5	23
29	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021, 73, 1073-1085.	5.6	81
30	Network meta-analysis of post-exposure prophylaxis randomized clinical trials. <i>HIV Medicine</i> , 2021, 22, 218-224.	2.2	2
31	Unilateral granulomatous mastitis in a pregnant woman as a first manifestation of sarcoidosis. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 406-408.	1.1	2
32	The Rheumatology Drugs for COVID-19 Management: Which and When?. <i>Journal of Clinical Medicine</i> , 2021, 10, 783.	2.4	18
33	Control del embarazo en pacientes con lupus eritematoso sistémico y síndrome antifosfolípido. Parte 1: Infertilidad, preservación ovárica y valoración preconcepcional. Documento de consenso de la Sociedad Española de Ginecología y Obstetricia (SEGO), Sociedad Española de Medicina Interna (SEMI) y Sociedad Española de Reumatología (SER). <i>Reumatología Clínica</i> , 2021, 17, 61-66.	0.5	3
34	The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia. <i>Clinical Rheumatology</i> , 2021, 40, 2057-2063.	2.2	13
35	Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes. <i>European Journal of Anaesthesiology</i> , 2021, 38, 916-922.	1.7	8
36	Control del embarazo en pacientes con lupus eritematoso sistémico/síndrome antifosfolípido. parte 2: seguimiento del embarazo. <i>Reumatología Clínica</i> , 2021, 17, 125-131.	0.5	5

#	ARTICLE	IF	CITATIONS
37	The extent of tubulointerstitial inflammation is an independent predictor of renal survival in lupus nephritis. <i>Journal of Nephrology</i> , 2021, 34, 1897-1905.	2.0	18
38	Beta α 2 α Glycoprotein α Deficiency Could Precipitate an Antiphospholipid Syndrome α Like Prothrombotic Situation in Patients With Coronavirus Disease 2019. <i>ACR Open Rheumatology</i> , 2021, 3, 267-276.	2.1	15
39	Successful treatment of two cases of refractory cutaneous lupus erythematosus with belimumab. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, 87, 421-424.	0.6	3
40	Causes of Hospitalization in Systemic Lupus Erythematosus: A Narrative Review. <i>Current Rheumatology Reviews</i> , 2021, 17, 29-40.	0.8	2
41	Control del embarazo en pacientes con lupus eritematoso sist α mico/s α ndrome antifosfol α pido. Parte 3. Parto. Puerperio. Lactancia. Anticoncepci α 3n. Reci α 3n nacido. <i>Reumatologα Clαnica</i> , 2021, 17, 183-186.	0.5	3
42	Unidades y asistencia multidisciplinar de uve α tis en los servicios de medicina interna en Espa α ±a: encuesta del Grupo de Enfermedades Autoinmunes Sist α micas. <i>Revista Clinica Espanola</i> , 2021, 221, 221-225.	0.6	4
43	Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 3: Childbirth. Puerperium. Breastfeeding contraception. Newborn. <i>Reumatologα Clαnica (English)</i> Tj ETQq1 1 0.784314 rgBT /@verlock	0.4	0
44	POS0767 α €...CLINICAL MANIFESTATIONS, TREATMENT, AND OUTCOMES OF α €œNON-CRITERIA α €•ANTIPHOSPHOLIPID SYNDROME IN COMPARISON WITH DEFINITE ANTIPHOSPHOLIPID SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 637-638.	0.9	0
45	AB0340 α €...PATIENTS WITH LABORATORY CRITERIA OF ANTIPHOSPHOLIPID SYNDROME AND α €œNON-CRITERIA α €• MANIFESTATIONS: A MULTICENTER STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1195.1-1195.	0.9	0
46	POS1371 α €...BIOLOGICAL THERAPY IN REFRACTORY NEUROBEH α ±ET α €™S DISEASE. MULTICENTER STUDY OF 42 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 967-968.	0.9	0
47	Impact of novel coronavirus infection in patients with uveitis associated with an autoimmune disease: Result of the COVID-19-GEAS patient survey. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2021, 96, 347-352.	0.2	3
48	POS1409 α €...AUTOMATED DETECTION OF SCLERODERMIFORM PATTERNS USING CAPILLARY.IO. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 987.2-988.	0.9	0
49	Management of patients with antiphospholipid antibodies: what to do in laboratory scenarios that do not fit the guidelines. <i>Expert Review of Hematology</i> , 2021, 14, 457-466.	2.2	4
50	POS1408 α €...REPRODUCIBILITY OF A NEW AUTOMATIC SYSTEM (CAPILLARY.IO) IN THE ANALYSIS OF NAILFOLD CAPILLAROSCOPY IMAGES. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 987.1-987.	0.9	0
51	Non-criteria Manifestations of Antiphospholipid Syndrome: An Overview. <i>Spanish Journal of Medicine</i> , 2021, 1, .	0.1	1
52	A new molecular classification to drive precision treatment strategies in primary Sj α gren α €™s syndrome. <i>Nature Communications</i> , 2021, 12, 3523.	12.8	67
53	Scleritis and sclerokeratitis associated with IgA vasculitis: A case series. <i>American Journal of Ophthalmology Case Reports</i> , 2021, 22, 101100.	0.7	3
54	Catastrophic antiphospholipid syndrome. <i>Revista Colombiana De Reumatologα</i> , 2021, 28, 39-43.	0.1	4

#	ARTICLE	IF	CITATIONS
55	Treat to target in systemic lupus erythematosus. <i>Revista Colombiana De Reumatología</i> , 2021, 28, 101-106.	0.1	1
56	Understanding tubulointerstitial injury and repair mechanisms paves the way for renal outcome improvement in lupus nephritis. <i>Revista Colombiana De Reumatología</i> , 2021, 28, 82-89.	0.1	1
57	The antiphospholipid syndrome. <i>Revista Colombiana De Reumatología</i> , 2021, 28, 166-176.	0.1	0
58	Bipolar disorder and Susac syndrome. <i>International Clinical Psychopharmacology</i> , 2021, Publish Ahead of Print, 305-309.	1.7	0
59	A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021, 73, 1550-1561.	5.6	24
60	Antimalarial-induced retinal toxicity. <i>Revista Colombiana De Reumatología</i> , 2021, 28, 132-143.	0.1	2
61	Obstetric outcomes in systemic sclerosis: looking inside the sealed box. <i>Rheumatology International</i> , 2021, , 1.	3.0	2
62	Enfermedades autoinmunes y vacunas contra la COVID-19. Toma de decisiones en escenarios de incertidumbre. <i>Medicina Clínica</i> , 2021, 157, 247-252.	0.6	4
63	VACOVEAS study, an observational survey on the adverse events associated with COVID-19 vaccines in patients with systemic autoimmune diseases. <i>European Journal of Internal Medicine</i> , 2021, 93, 110-111.	2.2	1
64	Autoimmune diseases and vaccines against COVID-19. Decision making in uncertain scenarios. <i>Medicina Clínica (English Edition)</i> , 2021, 157, 247-252.	0.2	9
65	Anti-Phosphatidylserine/Prothrombin Antibodies at Two Points: Correlation With Lupus Anticoagulant and Thrombotic Risk. <i>Frontiers in Immunology</i> , 2021, 12, 754469.	4.8	13
66	Anti-TNF-alpha-induced lupus in patients with non-infectious uveitis. <i>European Journal of Ophthalmology</i> , 2021, , 112067212110547.	1.3	1
67	Integrative epigenomics in Sjögren's syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature. <i>Scientific Reports</i> , 2021, 11, 23292.	3.3	16
68	Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study. <i>Journal of Rheumatology</i> , 2020, 47, 89-98.	2.0	11
69	Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. <i>Rheumatology</i> , 2020, 59, 1306-1314.	1.9	53
70	Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. <i>Rheumatology</i> , 2020, 59, 1574-1580.	1.9	47
71	Economic Analysis of the Use of Anti-DFS70 Antibody Test in Patients with Undifferentiated Systemic Autoimmune Disease Symptoms. <i>Journal of Rheumatology</i> , 2020, 47, 1275-1284.	2.0	9
72	Post-exposure prophylaxis for HIV infection in sexual assault victims. <i>HIV Medicine</i> , 2020, 21, 43-52.	2.2	12

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1299-1306.	3.4	16
74	Procoagulant microparticles are associated with arterial disease in patients with systemic lupus erythematosus. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 30-41.	2.1	1
75	Tuberculosis-Related Uveitis in Patients under Anti-TNF-alpha Therapy: A Case Series. <i>Ocular Immunology and Inflammation</i> , 2020, , 1-6.	1.8	1
76	Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 278.	3.5	7
77	Autologous Hematopoietic Stem Cell Transplantation for Susac Syndrome. <i>Annals of Internal Medicine</i> , 2020, 173, 315-317.	3.9	4
78	Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 134-135.	0.2	1
79	Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI). <i>RMD Open</i> , 2020, 6, e001192.	3.8	20
80	Non-criteria antiphospholipid syndrome: A nomenclature proposal. <i>Autoimmunity Reviews</i> , 2020, 19, 102689.	5.8	37
81	Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses. <i>RMD Open</i> , 2020, 6, e001355.	3.8	5
82	Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. , 2020, , .		1
83	Standardization procedure for flow cytometry data harmonization in prospective multicenter studies. <i>Scientific Reports</i> , 2020, 10, 11567.	3.3	20
84	Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. <i>Rheumatology</i> , 2020, 59, 3690-3699.	1.9	7
85	Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center. <i>Lupus</i> , 2020, 29, 1050-1059.	1.6	15
86	Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide. <i>Frontiers in Immunology</i> , 2020, 11, 865.	4.8	48
87	Spanish scleroderma risk score (RESCLESORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation. <i>Autoimmunity Reviews</i> , 2020, 19, 102507.	5.8	13
88	A virtual dairy herd as a tool to teach dairy production and management. <i>Journal of Dairy Science</i> , 2020, 103, 2896-2905.	3.4	10
89	IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. <i>Scientific Reports</i> , 2020, 10, 11010.	3.3	11
90	Precision medicine and the antiphospholipid syndrome: what is the future?. <i>Clinical Rheumatology</i> , 2020, 39, 1015-1017.	2.2	2

#	ARTICLE	IF	CITATIONS
91	Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases. <i>Medicine (United States)</i> , 2020, 99, e18589.	1.0	14
92	Le Relapsing Polychondritis Damage Index (RPDAM): développement d'un score clinique au cours de la polychondrite atrophiante. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020, 87, 122-127.	0.0	0
93	Treat-to-target in systemic lupus erythematosus: Where are we?. <i>European Journal of Internal Medicine</i> , 2020, 74, 29-34.	2.2	19
94	Hidroxicloroquina en el tratamiento del COVID-19: ¿cómo utilizarla a la espera de evidencia científica concluyente. <i>Medicina Clínica</i> , 2020, 155, 134-135.	0.6	5
95	SAT0274...DESCRIPTIVE ANALYSIS OF FLARES DURING THE LONG-TERM FOLLOW-UP OF PATIENTS WITH BEHÇET'S DISEASE INCLUDED IN REGB COHORT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1081.2-1081.	0.9	0
96	THU0307...RESPONSE OF BEHÇET'S REFRACTORY ORAL AND/OR GENITAL ULCERS TO APREMILAST IN COMBINATION VS MONOTHERAPY. NATIONAL MULTICENTER STUDY OF 51 CASES OF CLINICAL PRACTICE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 382.2-382.	0.9	0
97	FRI0487...APREMILAST IN MONOTHERAPY OR COMBINED IN NON-ULCER MANIFESTATIONS OF BEHÇET'S DISEASE. NATIONAL MULTICENTER STUDY OF 34 REFRACTORY CASES OF CLINICAL PRACTICE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 841.1-842.	0.9	0
98	SAT0316...ANTI-PM/SCL ANTIBODIES IN SYSTEMIC SCLEROSIS: CLINICAL ASSOCIATIONS IN THE RESCLE COHORT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1103.1-1104.	0.9	0
99	Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 220.e1-220.e12.	0.2	0
100	Connective tissue disease-associated interstitial lung diseases and interstitial pneumonia with autoimmune features: different entities?. , 2020, , .		0
101	Serodiscordant patients with systemic sclerosis: when antibody does not correspond to skin involvement. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 106-114.	0.8	1
102	Comparative study between two European inception cohorts of patients with early systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 925-932.	0.8	0
103	Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 69-75.	0.8	2
104	Recurrent Thrombosis With Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Systematic Literature Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2019, 41, 1839-1862.	2.5	27
105	Causes and factors related to hospitalizations in patients with systemic lupus erythematosus: analysis of a 20-year period (1995-2015) from a single referral centre in Catalonia. <i>Lupus</i> , 2019, 28, 1158-1166.	1.6	31
106	Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 469-473.	1.1	22
107	Identification of Indoor Fungal Antigens in Assessment of Hypersensitivity Pneumonitis - an Alternate Approach. , 2019, , .		0
108	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019, 10, 4955.	12.8	100

#	ARTICLE	IF	CITATIONS
109	Plasma exchange in catastrophic antiphospholipid syndrome. <i>Presse Medicale</i> , 2019, 48, 347-353.	1.9	12
110	Complications and visual acuity of patients with uveitis: Epidemiological study in a reference unit in northern Spain. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2019, 94, 419-425.	0.2	1
111	Treatment for refractory lupus nephritis: Rituximab vs triple target therapy. <i>Autoimmunity Reviews</i> , 2019, 18, 102406.	5.8	11
112	LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients. <i>Rheumatology International</i> , 2019, 39, 1875-1882.	3.0	8
113	Catastrophic Antiphospholipid Syndrome. , 2019, , 493-500.		0
114	Autoantibodies, elevated cytokines, and neurocognitive abnormalities in offspring of women with systemic lupus erythematosus: comparison with healthy controls. <i>Clinical Rheumatology</i> , 2019, 38, 2529-2539.	2.2	9
115	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. <i>Autoimmunity Reviews</i> , 2019, 18, 406-414.	5.8	106
116	Behçet's disease and genetic interactions between HLA-B*51 and variants in genes of autoinflammatory syndromes. <i>Scientific Reports</i> , 2019, 9, 2777.	3.3	21
117	THU0299â€¦PATIENT GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN BEHÇET'S SYNDROME: A MULTICENTER STUDY. , 2019, , .		0
118	FRI0270â€¦APREMILAST IN NON-ULCER MANIFESTATIONS IN BEHÇET'S DISEASE. MULTICENTER STUDY OF 32 CASES IN CLINICAL PRACTICE. , 2019, , .		0
119	THU0573â€¦COMPLICATIONS AND ACTIVITY OF UVEITIS IN A MULTIDISCIPLINARY REFERENCE UNIT IN THE NORTH OF SPAIN. , 2019, , .		0
120	OPO282â€¦OBSTETRIC ANTIPHOSPHOLIPID SYNDROME (OAPS) VS. WITH OBSTETRIC MORBIDITY RELATED WITH ANTIPHOSPHOLIPID ANTIBODIES (OMAPS): A SURVEY OF 1650 CASES FROM EUROAPS REGISTRY. , 2019, , .		0
121	SAT0240â€¦DEVELOPMENT AND PRELIMINARY VALIDATION OF THE BEHÇET'S SYNDROME OVERALL DAMAGE INDEX (BODI). , 2019, , .		0
122	AB0214â€¦MUSCLE INVOLVEMENT IN SYSTEMIC SCLEROSIS. , 2019, , .		0
123	SAT0215â€¦APREMILAST IN REFRACTORY ORAL AND/OR GENITAL ULCERS IN BEHÇET'S DISEASE. MULTICENTER STUDY OF 49 CASES IN CLINICAL PRACTICE. , 2019, , .		0
124	Association of Functional Polymorphisms of KIR3DL1/DS1 With Behçet's Disease. <i>Frontiers in Immunology</i> , 2019, 10, 2755.	4.8	17
125	The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. <i>Joint Bone Spine</i> , 2019, 86, 363-368.	1.6	8
126	Complicaciones y agudeza visual en los pacientes con uveitis en una unidad multidisciplinar de referencia del norte de Espaãa. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2019, 94, 419-425.	0.2	10

#	ARTICLE	IF	CITATIONS
127	Identification of indoor fungal antigens in assessment of hypersensitivity pneumonitis – an alternate approach. , 2019, , .		1
128	Association between allelic variants of the human glucocorticoid receptor gene and autoimmune diseases: A systematic review and meta-analysis. Autoimmunity Reviews, 2018, 17, 449-456.	5.8	9
129	The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Rheumatology, 2018, 57, 1264-1270.	1.9	70
130	Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. Medicina Clínica, 2018, 151, 215-222.	0.6	22
131	TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA. Retina, 2018, 38, 1361-1370.	1.7	70
132	First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. Clinical Rheumatology, 2018, 37, 999-1009.	2.2	27
133	All that glitters is not lupus. Lupus, 2018, 27, 1047-1048.	1.6	1
134	AB0561 – Infections in newly diagnosed spanish patients with systemic lupus erythematosus: data from the reles cohort. , 2018, , .		0
135	Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort. Lupus, 2018, 27, 2253-2261.	1.6	32
136	Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. Medicina Clínica (English Edition), 2018, 151, 215-222.	0.2	2
137	The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. Journal of Autoimmunity, 2018, 92, 1-11.	6.5	143
138	McMaster RARE – Best practices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2018, 16, 1656-1664.	3.8	95
139	AB0678 – Peripheral ulcerative keratitis associated to autoimmune systemic diseases: visual prognosis and occurrence while systemic disease in remission. , 2018, , .		0
140	The H1 haplotype of the endothelial protein C receptor protects against arterial thrombosis in patients with antiphospholipid syndrome. Thrombosis Research, 2018, 169, 128-134.	1.7	13
141	SAT0598 – Systematic literature review on the efficacy and safety of immunomodulatory drugs in patients with noninfectious intermediate and posterior uveitis, panuveitis and macular oedema. , 2018, , .		0
142	Late Breaking Abstract - SMOKING PREVALENCE AND CHARACTERIZATION OF PATIENTS AT DIAGNOSIS OF DIFFUSE INTERSTITIAL LUNG DISEASES. , 2018, , .		0
143	Venous thrombosis and relapses in patients with Behçet's disease. Descriptive analysis from Spanish network of Behçet's disease (REGEB cohort). Clinical and Experimental Rheumatology, 2018, 36, 40-44.	0.8	6
144	Fístulas arteriovenosas durales recurrentes en paciente con enfermedad de Behçet. Neurología, 2017, 32, 623-626.	0.7	1

#	ARTICLE	IF	CITATIONS
145	Caracterización de los pacientes con uveítis remitidos a una unidad multidisciplinar de referencia en el norte de España. Archivos De La Sociedad Espanola De Oftalmologia, 2017, 92, 202-209.	0.2	20
146	Características clínicas al diagnóstico de una cohorte prospectiva de pacientes con lupus eritematoso sistémico atendidos en servicios de Medicina Interna españoles: estudio RELES. Revista Clinica Espanola, 2017, 217, 7-14.	0.6	5
147	Successful Extracorporeal Membrane Oxygenation in a Patient With Fulminant Lupus Myocarditis. Revista Espanola De Cardiologia (English Ed), 2017, 70, 1013-1014.	0.6	2
148	Characterization of isolated retinal vasculitis. Analysis of a cohort from a single center and literature review. Autoimmunity Reviews, 2017, 16, 237-243.	5.8	25
149	Cardiac Involvement in the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, , 295-321.	0.1	0
150	Prognosis in Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, 12, 281-294.	0.1	0
151	Treatment of Catastrophic Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, , 243-255.	0.1	1
152	Brain abscess due to <i>Listeria monocytogenes</i> after HELLP syndrome in a patient with antiphospholipid syndrome. Lupus, 2017, 26, 1002-1004.	1.6	5
153	Advanced MRI techniques: biomarkers in neuropsychiatric lupus. Lupus, 2017, 26, 510-516.	1.6	33
154	Cessation of oral anticoagulants in antiphospholipid syndrome. Lupus, 2017, 26, 1347-1348.	1.6	0
155	Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre. Autoimmunity Reviews, 2017, 16, 750-755.	5.8	51
156	Clinical characteristics during diagnosis of a prospective cohort of patients with systemic lupus erythematosus treated in Spanish Departments of Internal Medicine: The RELES study. Revista Clínica Española, 2017, 217, 7-14.	0.5	0
157	Systemic lupus erythematosus exacerbation following cessation of belimumab treatment: comments on the article by Furer et al. Scandinavian Journal of Rheumatology, 2017, 46, 250-251.	1.1	2
158	Profile of patients with uveitis referred to a multidisciplinary unit in northern Spain. Archivos De La Sociedad Espanola De Oftalmologia, 2017, 92, 202-209.	0.2	3
159	Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology. Immunobiology, 2017, 222, 620-630.	1.9	15
160	Thrombotic Manifestations of the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, 12, 87-106.	0.1	1
161	Cardiac tamponade and severe pericardial effusion in systemic sclerosis: report of nine patients and review of the literature. International Journal of Rheumatic Diseases, 2017, 20, 1582-1592.	1.9	29
162	Recurrent dural arteriovenous fistulas in a patient with Behçet's disease. Neurología (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	0.4	0

#	ARTICLE	IF	CITATIONS
163	THU0549â€¦Systemic treatment for acute anterior uveitis (synthetic and biologic disease-modifying) Tj ETQq1 1 0.784314 rgBT /Overl		
164	Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.0	23
165	Mutational profile of rare variants in inflammasome-related genes in Behçet disease: A Next Generation Sequencing approach. Scientific Reports, 2017, 7, 8453.	3.3	29
166	Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconversion?. Autoimmunity Reviews, 2017, 16, 1109-1114.	5.8	19
167	Documento de recomendaciones de tratamiento de la uveitis anterior no infecciosa. Medicina Clínica, 2017, 149, 552.e1-552.e12.	0.6	14
168	Oxigenador extracorpóreo de membrana eficaz en una paciente con miocarditis lámpica fulminante. Revista Espanola De Cardiologia, 2017, 70, 1013-1014.	1.2	5
169	THU0561â€¦Clinical practice guideline for diagnosis and management of catastrophic antiphospholipid syndrome. , 2017, , .		0
170	Editorial al artículo: «Relación clínico-patológica en pacientes colombianos con nefritis lámpica». Revista Colombiana De Reumatología, 2017, 24, 197-198.	0.1	0
171	Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. Journal of Antimicrobial Chemotherapy, 2017, 72, 2857-2861.	3.0	12
172	Editorial to article: «Clinico-pathologic relationship in Colombian patients with lupus nephritis». Revista Colombiana De Reumatología (English Edition), 2017, 24, 197-198.	0.0	0
173	FRI0602â€¦National recommendations on the use of immunomodulatory drugs in patients with non-infectious non-malignant anterior uveitis. , 2017, , .		0
174	THU0569â€¦Treatments of uveitis in a referral multidisciplinary unit in northern Spain. , 2017, , .		0
175	OPO231â€¦The effect of «triple therapy» with anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulins on the mortality of catastrophic antiphospholipid syndrome (CAPS) patients. , 2017, , .		0
176	Digestive Involvement in the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, 13, 227-241.	0.1	0
177	An update on isolated retinal vasculitis. Minerva Oftalmologica, 2017, 59, .	0.1	0
178	15th International Congress on Antiphospholipid Antibodies Task Force on Catastrophic Antiphospholipid Syndrome Report. , 2017, , 307-316.		1
179	Catastrophic antiphospholipid syndrome: an update. Panminerva Medica, 2017, 59, 254-268.	0.8	34
180	Definition and Epidemiology of Antiphospholipid Syndrome. , 2017, , 147-169.		1

#	ARTICLE	IF	CITATIONS
181	Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE). <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 40-47.	0.8	6
182	Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 98-105.	0.8	8
183	Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies. <i>Antibodies</i> , 2016, 5, 18.	2.5	12
184	FRIO311â€¦Neuropsychiatric Lupus: Combining Advanced Morphometric Methods, Diffusion Tensor Imaging and Conventional MRI Leads To The Pathways of Brain Abnormalities. Correlation with Clinical and Laboratory Data. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 547.3-548.	0.9	0
185	Genetic Analysis with the Immunochip Platform in Behçet Disease. Identification of Residues Associated in the HLA Class I Region and New Susceptibility Loci. <i>PLoS ONE</i> , 2016, 11, e0161305.	2.5	48
186	First month prednisone dose predicts prednisone burden during the following 11â€¦months: an observational study from the RELES cohort. <i>Lupus Science and Medicine</i> , 2016, 3, e000153.	2.7	20
187	Congenital heart block related to maternal autoantibodies: descriptive analysis of a series of 18 cases from a single center. <i>Clinical Rheumatology</i> , 2016, 35, 351-356.	2.2	16
188	The problems and pitfalls in systemic lupus erythematosus drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 525-527.	5.0	7
189	Catastrophic antiphospholipid syndrome: The current management approach. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 239-249.	3.3	39
190	Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. <i>Autoimmunity Reviews</i> , 2016, 15, 1120-1124.	5.8	211
191	Rituximab action on the antiphospholipid antibodies in patients with thrombotic antiphospholipid syndrome. <i>Medicina Clínica (English Edition)</i> , 2016, 146, e69-e70.	0.2	0
192	Inherited thrombophilia in women with poor aPLâ€¦related obstetric history: prevalence and outcomes. Survey of 208â€¦cases from the European Registry on Obstetric Antiphospholipid Syndrome cohort. <i>American Journal of Reproductive Immunology</i> , 2016, 76, 164-171.	1.2	14
193	Repeated Renal Biopsy - A Predictive Tool to Assess the Probability of Renal Flare in Lupus Nephritis. <i>American Journal of Nephrology</i> , 2016, 44, 439-446.	3.1	21
194	International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies. <i>Lupus</i> , 2016, 25, 864-872.	1.6	26
195	A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1982-1986.	3.0	9
196	A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1987-1993.	3.0	16
197	Auscultation of Velcro Crackles is Associated With Usual Interstitial Pneumonia. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlock</i>	1.0	35
198	Renal tubular acidosis type IV as a complication of lupus nephritis. <i>Lupus</i> , 2016, 25, 307-309.	1.6	8

#	ARTICLE	IF	CITATIONS
199	Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center. <i>Autoimmunity Reviews</i> , 2016, 15, 9-15.	5.8	62
200	Procoagulant microparticles are increased in patients with Behçet's disease but do not define a specific subset of clinical manifestations. <i>Clinical Rheumatology</i> , 2016, 35, 695-699.	2.2	9
201	Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 526-531.	0.9	157
202	Behçet's Disease. , 2016, , 202-210.		0
203	Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 466-72.	0.8	7
204	PTPN22 is not associated with Behçet's disease. Study spanning the complete gene region in the Spanish population and meta-analysis of the functional variant R620W. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S41-S45.	0.8	2
205	Thrombotic Microangiopathy: a Challenging Diagnosis Always. <i>Israel Medical Association Journal</i> , 2016, 18, 437-438.	0.1	0
206	ADAMTS-13 in Critically Ill Patients With Septic Syndromes and Noninfectious Systemic Inflammatory Response Syndrome. <i>Shock</i> , 2015, 43, 556-562.	2.1	35
207	FRIO418...Outcome of the Autoimmune Congenital Heart Block in 45 Babies from Anti-RO/LA (+) Mothers: Results from the Spanish Registry (Rebacc-Geas-Semi). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 578.1-578.	0.9	0
208	Epidemiology of uveitis in a Western urban multiethnic population. The challenge of globalization. <i>Acta Ophthalmologica</i> , 2015, 93, 561-567.	1.1	104
209	Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus. <i>Clinical Investigation</i> , 2015, 5, 561-571.	0.0	4
210	AB0009...The HLA Class I Region in Behçet's Disease: Identifying the Most Relevant Amino Acid Positions. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 894.1-894.	0.9	0
211	SAT0534...Thrombosis and Re-Thrombosis Manifestations in Patients with Behçet Disease. Descriptive Analysis from Regeb Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 853.2-854.	0.9	0
212	Registry of the Spanish Network for Systemic Sclerosis. <i>Medicine (United States)</i> , 2015, 94, e1728.	1.0	73
213	FRIO403...Heart Valvular Involvement in the Antiphospholipid Syndrome. An Echocardiographic Descriptive Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 572.2-572.	0.9	0
214	A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. <i>Lupus Science and Medicine</i> , 2015, 2, e000123-e000123.	2.7	155
215	AB0718...Cardiac Tamponade and Severe Pericardial Effusion in Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1138.2-1138.	0.9	0
216	Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: Analysis of 24 cases from the bibliography review. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 97-104.	0.2	12

#	ARTICLE	IF	CITATIONS
217	What is the best strategy in treating catastrophic antiphospholipid syndrome?. International Journal of Clinical Rheumatology, 2015, 10, 245-255.	0.3	3
218	Catastrophic APS in the Context of Other Thrombotic Microangiopathies. Current Rheumatology Reports, 2015, 17, 482.	4.7	46
219	Development and validation of a risk calculator to differentiate flares from infections in systemic lupus erythematosus patients with fever. Autoimmunity Reviews, 2015, 14, 586-593.	5.8	38
220	SAT0544â€¦Comparing New and Classical Diagnostic Criteria in Behçet Disease (BD). Annals of the Rheumatic Diseases, 2015, 74, 857.2-857.	0.9	0
221	Current treatment of antiphospholipid syndrome: lights and shadows. Nature Reviews Rheumatology, 2015, 11, 586-596.	8.0	93
222	Rituximab and its therapeutic potential in catastrophic antiphospholipid syndrome. Therapeutic Advances in Musculoskeletal Disease, 2015, 7, 26-30.	2.7	20
223	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases. Autoimmunity Reviews, 2015, 14, 387-395.	5.8	121
224	Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus. Lupus, 2015, 24, 1143-1149.	1.6	12
225	Variants of the <i>IFI16</i> Gene Affecting the Levels of Expression of mRNA Are Associated with Susceptibility to Behçet Disease. Journal of Rheumatology, 2015, 42, 695-701.	2.0	17
226	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Annals of the Rheumatic Diseases, 2015, 74, 1011-1018.	0.9	610
227	Brain abnormalities in newly diagnosed neuropsychiatric lupus: Systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmunity Reviews, 2015, 14, 153-159.	5.8	106
228	The. Rare Diseases of the Immune System, 2015, , 249-262.	0.1	98
229	Behçetâ€™s Disease. , 2015, , 1-9.		0
230	Lack of association of TNFAIP3 and JAK1 with Behçet's disease in the European population. Clinical and Experimental Rheumatology, 2015, 33, S36-9.	0.8	4
231	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. Clinical and Experimental Rheumatology, 2015, 33, S31-5.	0.8	4
232	Association of CCR5 ^{Î”32} and Behçet's disease: new data from a case-control study in the Spanish population and meta-analysis. Clinical and Experimental Rheumatology, 2015, 33, S96-100.	0.8	1
233	Association of haplotypes of the TLR8 locus with susceptibility to Crohn's and Behçet's diseases. Clinical and Experimental Rheumatology, 2015, 33, S117-22.	0.8	24
234	Epistatic Interaction of ERAP1 and HLA-B in Behçet Disease: A Replication Study in the Spanish Population. PLoS ONE, 2014, 9, e102100.	2.5	30

#	ARTICLE	IF	CITATIONS
235	Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2014, 41, 1895-1896.	2.0	19
236	Proinflammatory Cytokines and C-Reactive Protein in Uveitis Associated with Behçet's Disease. <i>Mediators of Inflammation</i> , 2014, 2014, 1-8.	3.0	30
237	Diagnosing catastrophic antiphospholipid syndrome: the necessity for clinical awareness. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 1-3.	0.3	1
238	Renal Transplantation in Systemic Lupus Erythematosus: Outcome and Prognostic Factors in 50 Cases from a Single Centre. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	19
239	Early- versus Late-Onset Systemic Sclerosis. <i>Medicine (United States)</i> , 2014, 93, 73-81.	1.0	61
240	Anti-MDA5 positive clinically amyopathic dermatomyositis presenting with severe cardiomyopathy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1097-1102.	2.4	24
241	Longitudinally extensive myelitis in a patient with characteristic autoantibody profile of systemic lupus erythematosus: a challenging etiological diagnosis. <i>Lupus</i> , 2014, 23, 1555-1556.	1.6	1
242	Current and future treatments for Behçet's uveitis: road to remission. <i>International Ophthalmology</i> , 2014, 34, 365-381.	1.4	38
243	A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. <i>Arthritis Research and Therapy</i> , 2014, 16, R6.	3.5	37
244	Pediatric catastrophic antiphospholipid syndrome: Descriptive analysis of 45 patients from the CAPS Registry. <i>Autoimmunity Reviews</i> , 2014, 13, 157-162.	5.8	88
245	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). <i>Rheumatology</i> , 2014, 53, 275-284.	1.9	71
246	ImmunoChIP Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	6.2	182
247	GIMAP and Behçet disease: no association in the European population: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1433-1434.	0.9	17
248	ABO631...Anti-Rna Polymerase III and anti Pm/Scl Antibodies: Prevalence and Clinical Associations in A Large Cohort of Spanish Patients with Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1014.2-1014.	0.9	0
249	Registry of the Spanish network of Behçet's disease: a descriptive analysis of 496 patients. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S33-9.	0.8	17
250	Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S67-71.	0.8	3
251	Catastrophic antiphospholipid syndrome: an orchestra with several musicians. <i>Israel Medical Association Journal</i> , 2014, 16, 585-6.	0.1	8
252	Neuropsychiatric systemic lupus erythematosus: Magnetic resonance imaging findings and correlation with clinical and immunological features. <i>Autoimmunity Reviews</i> , 2013, 12, 1166-1170.	5.8	77

#	ARTICLE	IF	CITATIONS
253	Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. <i>Immunologic Research</i> , 2013, 56, 358-361.	2.9	48
254	Tocilizumab treatment for refractory uveitis-related cystoid macular edema. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 2627-2632.	1.9	103
255	Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. <i>Autoimmunity Reviews</i> , 2013, 12, 1085-1090.	5.8	211
256	Congenital heart block related with maternal autoimmune diseases: Descriptive analysis of a series of 17 cases. <i>European Journal of Internal Medicine</i> , 2013, 24, e130-e131.	2.2	0
257	Mortality prognostic factors of patients with systemic autoimmune diseases admitted to an intensive care unit. <i>European Journal of Internal Medicine</i> , 2013, 24, e114.	2.2	2
258	Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity. <i>Arthritis Research and Therapy</i> , 2013, 15, R41.	3.5	55
259	Association of allelic variants of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase with thrombosis or ocular involvement in Behçet's disease: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2013, 12, 607-616.	5.8	32
260	Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behçet's disease. <i>Human Immunology</i> , 2013, 74, 230-233.	2.4	30
261	Pars Plana Vitrectomy for Vitreoretinal Complications of Behçet Uveitis. <i>European Journal of Ophthalmology</i> , 2013, 23, 119-128.	1.3	10
262	Relapsing Catastrophic Antiphospholipid Syndrome Potential Role of Microangiopathic Hemolytic Anemia in Disease Relapses. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 417-423.	3.4	34
263	Catastrophic Antiphospholipid Syndrome. <i>Clinics in Laboratory Medicine</i> , 2013, 33, 391-400.	1.4	26
264	Behçet Disease-associated Uveitis Successfully Treated with Golimumab. <i>Ocular Immunology and Inflammation</i> , 2013, 21, 160-162.	1.8	71
265	Immunosuppression and Chagas Disease: A Management Challenge. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e1965.	3.0	97
266	The anti-phospholipid syndrome: 30 years in the forefront (1983-2013). <i>Rheumatology</i> , 2013, 52, 1347-1348.	1.9	1
267	High Prevalence of Prothrombotic Abnormalities in Multifocal Osteonecrosis. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlock 10</i>	1.0	27
268	Confirmation of <i>TNIP1</i> but not <i>RHOB</i> and <i>PSORS1C1</i> as systemic sclerosis risk factors in a large independent replication study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 602-607.	0.9	56
269	Implication of <i>IL-2/IL-21</i> region in systemic sclerosis genetic susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1233-1238.	0.9	30
270	A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. <i>Human Molecular Genetics</i> , 2013, 22, 4021-4029.	2.9	104

#	ARTICLE	IF	CITATIONS
271	HLA and non-HLA genes in Behçet's disease: a multicentric study in the Spanish population. <i>Arthritis Research and Therapy</i> , 2013, 15, R145.	3.5	50
272	FRIO338...Multicenter study of tumour necrosis factor alpha antagonists for refractory behçet's uveitis in Spain. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A488.3-A489.	0.9	0
273	FRIO213...Anti-TNF therapy in refractory uveitis of behçet's syndrome. A multicenter study of 63 patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 386.1-386.	0.9	3
274	THU0278...Rituximab in Catastrophic Antiphospholipid Syndrome: A Potential Therapeutic Option. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A259.2-A260.	0.9	0
275	Catastrophic Antiphospholipid Syndrome - 20 Years Later. <i>Current Rheumatology Reviews</i> , 2013, 9, 73-80.	0.8	10
276	Heart Valve Surgery and the Antiphospholipid Syndrome. , 2013, , 321-329.		0
277	Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome?. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 926-32.	0.8	13
278	Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a case-control study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 61-66.	0.9	55
279	Update on the Catastrophic Antiphospholipid Syndrome and the "CAPS Registry" Seminars in Thrombosis and Hemostasis, 2012, 38, 333-338.	2.7	79
280	The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis. <i>Genes and Immunity</i> , 2012, 13, 191-196.	4.1	23
281	Lymphoplasmacytic lymphoma causing light chain cast nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 450-453.	0.7	19
282	Classification criteria for SLE: the latest "but not least" attempt. <i>Nature Reviews Rheumatology</i> , 2012, 8, 506-507.	8.0	7
283	Adalimumab for the treatment of Behçet's disease: experience in 19 patients. <i>Rheumatology</i> , 2012, 51, 1825-1831.	1.9	87
284	Influence of the IL6 Gene in Susceptibility to Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 2294-2302.	2.0	34
285	Venous thromboembolic disease in systemic autoimmune diseases: An association to keep in mind. <i>Autoimmunity Reviews</i> , 2012, 12, 289-294.	5.8	12
286	Catastrophic antiphospholipid syndrome triggered by fulminant disseminated herpes simplex infection in a patient with systemic lupus erythematosus. <i>Lupus</i> , 2012, 21, 1359-1361.	1.6	16
287	Val247Leu beta2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: Systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2012, 11, 705-712.	5.8	23
288	Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R154.	3.5	11

#	ARTICLE	IF	CITATIONS
289	A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R85.	3.5	32
290	Cardiac valve replacement in patients with antiphospholipid syndrome. <i>Arthritis Care and Research</i> , 2012, 64, n/a-n/a.	3.4	32
291	No evidence of association between functional polymorphisms located within <sc><i>IL6R</i></sc> and <sc><i>IL6ST</i></sc> genes and systemic sclerosis. <i>Tissue Antigens</i> , 2012, 80, 254-258.	1.0	4
292	Task Force Report on Catastrophic Antiphospholipid Syndrome. , 2012, , 181-193.		0
293	Task Force Report on Non-criteria Manifestations: Cardiac Valve Disease. , 2012, , 223-233.		0
294	Experiencia en el tratamiento de las uveítis con agentes anti-TNF- α en la Unidad de Uveítis del Hospital Cl�nico de Barcelona. , 2012, , 91-96.		0
295	Heart Valve Lesions In The Antiphospholipid Syndrome. <i>Current Rheumatology Reviews</i> , 2012, 8, 161-165.	0.8	0
296	Mortality and long term survival prognostic factors of patients with systemic autoimmune diseases admitted to an intensive care unit: a retrospective study. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 338-44.	0.8	19
297	Current management of catastrophic antiphospholipid syndrome. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 297-303.	0.3	3
298	Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. <i>Lupus</i> , 2011, 20, 165-173.	1.6	91
299	Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. <i>Lupus</i> , 2011, 20, 721-729.	1.6	39
300	Treatment of Antiphospholipid Syndrome. , 2011, , 1027-1042.		0
301	Therapeutic Perspectives in the Antiphospholipid Syndrome. <i>Current Rheumatology Reviews</i> , 2011, 7, 313-321.	0.8	0
302	Eficacia de la ciclofosfamida endovenosa en el tratamiento de la enfermedad pulmonar intersticial asociada a la esclerosis sist�mica. <i>Archivos De Bronconeumologia</i> , 2011, 47, 239-245.	0.8	10
303	Solid cancer, antiphospholipid antibodies, and venous thromboembolism. <i>Autoimmunity Reviews</i> , 2011, 10, 222-227.	5.8	33
304	Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: Report of 31 cases and review of the literature. <i>Autoimmunity Reviews</i> , 2011, 10, 679-684.	5.8	58
305	Management of refractory cases of catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2011, 10, 664-668.	5.8	75
306	Epidemiology and management of refractory lupus nephritis. <i>Autoimmunity Reviews</i> , 2011, 10, 655-663.	5.8	60

#	ARTICLE	IF	CITATIONS
307	A replication study confirms the association of <i>TNFSF4 (OX40L)</i> polymorphisms with systemic sclerosis in a large European cohort. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 638-641.	0.9	63
308	Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. <i>Lupus</i> , 2011, 20, 174-181.	1.6	93
309	Epidemiology and clinical outcomes of bloodstream infections among lupus patients. <i>Lupus</i> , 2011, 20, 965-971.	1.6	26
310	Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 454-462.	0.9	75
311	Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population. <i>Rheumatology</i> , 2011, 50, 1976-1981.	1.9	27
312	Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2050-2052.	0.9	15
313	Editorial [Hot Topic: Organ Involvement in the Antiphospholipid Syndrome (Guest Editors: Gerard Tj ETQq1 1 0.784314 rgBT ₀ /Overlook	0.8	0
314	Management of the antiphospholipid syndrome. <i>Autoimmunity Highlights</i> , 2010, 1, 15-22.	3.9	6
315	Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions. <i>International Ophthalmology</i> , 2010, 30, 577-581.	1.4	42
316	Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies. <i>Journal of Reproductive Immunology</i> , 2010, 86, 133-140.	1.9	15
317	Transverse Myelitis Affecting More Than 4 Spinal Segments Associated with Systemic Lupus Erythematosus: Clinical, Immunological, and Radiological Characteristics of 22 Patients. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 39, 246-256.	3.4	97
318	Factors influencing polyautoimmunity in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2010, 9, 229-232.	5.8	60
319	Etiopathogenesis of Behçet's disease. <i>Autoimmunity Reviews</i> , 2010, 9, 241-245.	5.8	161
320	Catastrophic antiphospholipid syndrome: Updated diagnostic algorithms. <i>Autoimmunity Reviews</i> , 2010, 10, 74-79.	5.8	152
321	Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. <i>Arthritis and Rheumatism</i> , 2010, 62, 1147-1152.	6.7	176
322	Genotypes Coding for Low Serum Levels of Mannose-Binding Lectin Are Underrepresented among Individuals Suffering from Noninfectious Systemic Inflammatory Response Syndrome. <i>Vaccine Journal</i> , 2010, 17, 447-453.	3.1	8
323	Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. <i>Nature Reviews Rheumatology</i> , 2010, 6, 296-300.	8.0	54
324	Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. <i>European Journal of Cardio-thoracic Surgery</i> , 2010, 37, 154-158.	1.4	50

#	ARTICLE	IF	CITATIONS
325	Antiphospholipid syndrome: long-time research on pathogenic mechanisms has finally lead to new therapeutic strategies. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1279-1282.	3.4	5
326	Successful Treatment with Posaconazole of a Patient with Chronic Chagas Disease and Systemic Lupus Erythematosus. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 82, 583-587.	1.4	121
327	Recent trends in the management of antiphospholipid syndrome (Hughes syndrome). <i>Drugs of Today</i> , 2010, 46, 39.	1.1	3
328	Belimumab, a BlyS-specific inhibitor for the treatment of systemic lupus erythematosus. <i>Drugs of Today</i> , 2010, 46, 891.	1.1	7
329	Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome. <i>Current Rheumatology Reviews</i> , 2010, 6, 3-11.	0.8	2
330	Chronic thromboembolic pulmonary hypertension in Behçet's disease: effectiveness of endarterectomy. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S79-81.	0.8	4
331	Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels. <i>Thrombosis and Haemostasis</i> , 2009, 101, 312-316.	3.4	22
332	Unusual manifestations of the antiphospholipid syndrome. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 189-202.	0.3	2
333	The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome. <i>Lupus</i> , 2009, 18, 905-912.	1.6	51
334	Catastrophic Antiphospholipid Syndrome: Treatment, Prognosis, and the Risk of Relapse. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 36, 80-84.	6.5	44
335	ORIGINAL ARTICLE: Thrombin Activatable Fibrinolysis Inhibitor and Clot Lysis Time in Pregnant Patients with Antiphospholipid Syndrome: Relationship with Pregnancy Outcome and Thrombosis. <i>American Journal of Reproductive Immunology</i> , 2009, 62, 381-389.	1.2	8
336	Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2009, 41, e4-e7.	0.9	14
337	Chapter 8 Systemic Manifestations of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, , 105-116.	0.1	5
338	Thromboprophylaxis and obstetric management of the antiphospholipid syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 601-614.	1.8	14
339	Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1428-1432.	0.9	262
340	Morbidity and mortality in the antiphospholipid syndrome. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 413-417.	2.6	15
341	Relapsing Catastrophic Antiphospholipid Syndrome: Report of Three Cases. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 37, 366-372.	3.4	62
342	Amputation of Digits or Limbs in Patients with Antiphospholipid Syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 38, 124-131.	3.4	37

#	ARTICLE	IF	CITATIONS
343	Antiphospholipid syndrome. <i>Arthritis Research and Therapy</i> , 2008, 10, 230.	3.5	24
344	Chapter 4 Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008, 8, 39-49.	0.1	0
345	Chapter 9 Adrenal Involvement in Systemic Autoimmune Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008, 9, 95-101.	0.1	0
346	Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo?. <i>Trends in Immunology</i> , 2008, 29, 280-289.	6.8	14
347	Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 835-840.	0.9	33
348	Delayed lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1044-1046.	0.9	26
349	Morbidity and Mortality in the Catastrophic Antiphospholipid Syndrome: Pathophysiology, Causes of Death, and Prognostic Factors. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 290-294.	2.7	58
350	Behçet Disease. , 2008, , 113-116.		0
351	Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients. <i>Lupus</i> , 2007, 16, 366-373.	1.6	45
352	Treatment of ANCA-Associated Vasculitis—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2739.	7.4	0
353	Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 655.	7.4	166
354	Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 740-746.	0.9	89
355	Intestinal Involvement Secondary to the Antiphospholipid Syndrome (APS): Clinical and Immunologic Characteristics of 97 Patients: Comparison of Classic and Catastrophic APS1. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 36, 287-296.	3.4	63
356	Catastrophic Antiphospholipid Syndrome: Lessons from the "CAPS Registry" A Tribute to the Late Josep Font. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 448-456.	3.8	25
357	Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent. <i>Intensive Care Medicine</i> , 2007, 33, 1354-1362.	8.2	45
358	The role of malignancies in patients with catastrophic anti-phospholipid (Asherson's) syndrome. <i>Clinical Rheumatology</i> , 2007, 26, 2109-2114.	2.2	23
359	The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. <i>Journal of Rheumatology</i> , 2007, 34, 346-52.	2.0	77
360	Catastrophic antiphospholipid syndrome and sepsis. A common link?. <i>Journal of Rheumatology</i> , 2007, 34, 923-6.	2.0	45

#	ARTICLE	IF	CITATIONS
361	Allelic Diversity and Affinity Variants of MICA are Imbalanced in Spanish Patients with Behcet's Disease. <i>Scandinavian Journal of Immunology</i> , 2006, 64, 77-82.	2.7	39
362	Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the "Euro-Lupus Project". <i>Autoimmunity Reviews</i> , 2006, 5, 180-186.	5.8	115
363	Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2006, 6, 68-71.	5.8	28
364	Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors. <i>Autoimmunity Reviews</i> , 2006, 6, 72-75.	5.8	83
365	Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. <i>Autoimmunity Reviews</i> , 2006, 6, 81-84.	5.8	30
366	Pregnancy and puerperium are high susceptibility periods for the development of catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2006, 6, 85-88.	5.8	20
367	Antiphospholipid Antibodies Associated with Malignancies: Clinical and Pathological Characteristics of 120 Patients. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 35, 322-332.	3.4	122
368	Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients. <i>Arthritis and Rheumatism</i> , 2006, 54, 2568-2576.	6.7	294
369	The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 81-86.	0.9	66
370	Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: A prospective, long-term, followup study. <i>Arthritis and Rheumatism</i> , 2005, 53, 460-467.	6.7	72
371	Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. <i>British Journal of Rheumatology</i> , 2005, 44, 95-99.	2.3	55
372	Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1205-1209.	0.9	209
373	Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 943-946.	0.9	74
374	Behçet's disease and hereditary periodic fever syndromes: casual association or causal relationship?. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, S64-6.	0.8	18
375	Pulmonary Involvement in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2004, 2, 137-145.	0.1	4
376	Quality and effectiveness of an emergency department during weekends. <i>Emergency Medicine Journal</i> , 2004, 21, 573-574.	1.0	13
377	Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 730-736.	0.9	133
378	Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1312-1317.	0.9	161

#	ARTICLE	IF	CITATIONS
379	Sedation for cardioversion in the emergency department. <i>Annals of Emergency Medicine</i> , 2003, 42, 767-772.	0.6	89
380	The 4G/4G genotype of the 4G/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1039-1047.	3.7	14
381	Saturación del servicio de urgencias: factores asociados y cuantificación. <i>Medicina Clínica</i> , 2003, 121, 167-172.	0.6	15
382	Antiphospholipid syndrome: pathogenic mechanisms. <i>Autoimmunity Reviews</i> , 2003, 2, 86-93.	5.8	70
383	Analysis of patient flow in the emergency department and the effect of an extensive reorganisation. <i>Emergency Medicine Journal</i> , 2003, 20, 143-148.	1.0	120
384	Long term outcome of catastrophic antiphospholipid syndrome survivors. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 530-533.	0.9	126
385	Adrenal involvement in the antiphospholipid syndrome. <i>Lupus</i> , 2003, 12, 569-572.	1.6	41
386	Adrenal Involvement in the Antiphospholipid Syndrome. <i>Medicine (United States)</i> , 2003, 82, 106-118.	1.0	175
387	Trends in Illicit Drug Emergencies: The Emerging Role of Gamma-Hydroxybutyrate. <i>Journal of Toxicology: Clinical Toxicology</i> , 2002, 40, 129-135.	1.5	89
388	The lung in the antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 195-198.	0.9	123
389	Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus. <i>Lupus</i> , 2002, 11, 730-735.	1.6	25
390	Catastrophic Antiphospholipid Syndrome. <i>Journal of Clinical Rheumatology</i> , 2002, 8, 157-165.	0.9	53
391	Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. <i>American Journal of Medicine</i> , 2002, 112, 37-43.	1.5	163
392	Effects of external and internal factors on emergency department overcrowding. <i>Annals of Emergency Medicine</i> , 2002, 39, 693-695.	0.6	49
393	Effects of Î²2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions. <i>Arthritis and Rheumatism</i> , 2002, 46, 3283-3289.	6.7	20
394	Myelodysplastic and Myeloproliferative Syndromes Associated with Giant Cell Arteritis and Polymyalgia Rheumatica: A Coincidental Coexistence or a Causal Relationship?. <i>Clinical Rheumatology</i> , 2002, 21, 309-313.	2.2	75
395	Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome. , 2002, , 169-188.		4
396	Hematological Abnormalities in the Antiphospholipid Syndrome. , 2002, , 259-270.		1

#	ARTICLE	IF	CITATIONS
397	Vascular involvement in Behçet's disease. Israel Medical Association Journal, 2002, 4, 614-6.	0.1	13
398	Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. Journal of Clinical Rheumatology, 2002, 8, 157-65.	0.9	20
399	The 4G/5G polymorphism of the type-1 plasminogen activator inhibitor gene is a determinant of disease phenotype and thrombotic events in patients with inflammatory bowel disease. Gastroenterology, 2001, 120, A457.	1.3	0
400	Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. Annals of Neurology, 2001, 49, 408-411.	5.3	42
401	Antiphospholipid antibodies and thrombophilic factors in giant cell arteritis. Seminars in Arthritis and Rheumatism, 2001, 31, 12-20.	3.4	47
402	Cardiac toxicity secondary to long term treatment with chloroquine. Annals of the Rheumatic Diseases, 2001, 60, 301-302.	0.9	55
403	Budd-Chiari Syndrome Secondary to Antiphospholipid Syndrome. Medicine (United States), 2001, 80, 345-354.	1.0	95
404	Catastrophic Antiphospholipid Syndrome. Medicine (United States), 2001, 80, 355-377.	1.0	342
405	The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis and Rheumatism, 2000, 43, 2349-2358.	6.7	69
406	Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. Haematologica, 2000, 85, 632-7.	3.5	43
407	Identification of a natural soluble form of human CD5. Tissue Antigens, 1999, 54, 128-137.	1.0	38
408	Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Seminars in Arthritis and Rheumatism, 1999, 29, 182-190.	3.4	114
409	Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Annals of the Rheumatic Diseases, 1998, 57, 456-459.	0.9	236
410	Young Onset of Primary Sjögren's syndrome: clinical and immunological characteristics. Lupus, 1998, 7, 202-206.	1.6	88
411	Hepatitis C virus infection in 'primary' Sjogren's syndrome: prevalence and clinical significance in a series of 90 patients. Annals of the Rheumatic Diseases, 1997, 56, 173-175.	0.9	82
412	Optic neuropathy in the 'primary' antiphospholipid syndrome: Report of a case and review of the literature. Clinical Rheumatology, 1997, 16, 629-631.	2.2	30
413	Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients. Clinical and Experimental Rheumatology, 1997, 15, 143-9.	0.8	32
414	Clinical Manifestations and Diagnosis of Behçet's Syndrome. European Medical Journal Rheumatology, 0, , 94-104.	0.0	0

#	ARTICLE	IF	CITATIONS
415	Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
416	Patients with laboratory criteria of anti-phospholipid syndrome and "non-criteria"™ manifestations: a multicenter cohort. <i>Scandinavian Journal of Rheumatology</i> , 0, , 1-6.	1.1	0